see below
More ... latest change: 2026-02-08
White Diamond Research published on Aytu Biopharma (NASDAQ: AYTU — $13 million), a pharmaceutical company focused on ADHD treatments. White Diamond alleged that starting in September 2025, the company’s ADHD portfolio “will be completely replaced by generics from Teva.” 2026-01-30 USD 2.6
last updated: